Vivos Therapeutics (NASDAQ: VVOS) Medical Advisor Board has been invited to present at the upcoming World Sleep Congress. The event, slated for March 11–16, 2022, will be held in Rome. Members of the board will be presenting a summary review of sleep-therapy data from patients treated with the Vivos Method. Vivos is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults. The World Sleep Congress has built a reputation for being one of the largest global conferences dedicated to sleep medicine research. Physicians, dentists, researchers and other professionals attend the gathering to learn about emerging technologies and therapies within sleep medicine. According to the announcement, the Vivos presentation, given by Dr. Seth Heckman, MD, is scheduled for March 15. “We are very pleased to accept the invitation to deliver an oral presentation at this prestigious sleep medicine conference,” said Vivos Medical Advisory Board cochair Dr. Cecilia Wu in the press release. “Our team has been working hard to enhance and strengthen the scientific foundation underlying Vivos’ technology, and our presentation at the World Sleep Congress is just the beginning of our scientific output.”
To view the full press release, visit https://ibn.fm/LBIEq
About Vivos Therapeutics Inc.
Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”). The Vivos Method represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for adults with dentofacial anomalies and/or mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos’ oral appliances have proven effective in the treatment of more than 24,000 patients worldwide by more than 1,350 trained dentists. Combining proprietary technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology, powered by VivosScore for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentist training and other value-added services in connection with using the Vivos System. For more information about this company, visit www.VivosLife.com.
NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
